Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic + Certican versus Myfortic + Sandimmun Optoral in de novo renal transplant patients
2004-004346-40Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium, everolimus and cyclosporine in kidney transplant (2 arms), sponsored by Novartis. Primary endpoint: Renal function assessed by GFR using the Nankivell method. Started Mar 2005; status: completed.
02
Drugs
mycophenolate sodiumeverolimuscyclosporine
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2004-004346-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004346-40.